FILANA THERAPEUTICS, INC. (FLNA) research
FILANA THERAPEUTICS, INC.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $0.74
- As of
FILANA THERAPEUTICS, INC. (FLNA): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-22.
As of . Source: SEC EDGAR filings for FLNA. Method and limitations.
Share the FLNA intelligence card
See FLNA live in the terminal
Track FLNA's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live FLNA terminal, freeActive signals for FLNA
- highINSTITUTIONAL_EXIT
Point72 Asset Management, L.P. cut 70% of FLNA (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 56% of FLNA (2026Q2)
- highINSTITUTIONAL_EXIT
Point72 Asset Management, L.P. cut 70% of FLNA (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 56% of FLNA (2026Q2)
- highINSTITUTIONAL_EXIT
Point72 Asset Management, L.P. cut 70% of FLNA (2026Q2)
FREE, NO ACCOUNT
Every signal on FLNA, as it fires
You are seeing 5 of 14 signals recorded on FLNA since 2026-05-29.
The five above landed across 2 days. The other 9 were recorded on 2 other days. 11 of the 14 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in FLNA (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| TWO SIGMA INVESTMENTS, LPCUSIP 14817C107 · 2026Q2 | $2M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 14817C107 · 2026Q2 | $577K | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 14817C107 · 2026Q2 | $464K | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 14817C107 · 2026Q2 | $14K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, FLNA
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
FLNA against its peers
FLNA's return on equity of -122.3% ranks in the 43rd percentile of 14 Biotechnology sub-industry peers, fiscal periods ending between 2025-07-31 and 2025-12-31.
| Metric | FLNA | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 2.2M | n/a | 13 |
| Operating margin | n/a | -709.4% | n/a | 10 |
| Net margin | n/a | -510.8% | n/a | 10 |
| Return on equity | -122.3% | -106.1% | 43 | 14 |
Peers (20): CRVO, GNTA, EDSA, CNTX, CELU, VERU, ATYR, KPTI, ALGS, KYNB, NXTC, MGX, ATNM, BCTX, BYSI, ANVS, MREO, SGMO, BRNS, QNCX. Left out: SEOVF (no annual filing), LITS (no annual filing), BETRF (period gap), CLCS (period gap), VICP (period gap). Fiscal periods ending between 2025-07-31 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (FLNA: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more FLNA signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to FLNAand get the insider, 13F, options, and confluence read in one view.